Younes, Anas <br/><br/>
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  05 2019 
 - 1285-1295 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.18.02403  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Double-Blind Method<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Piperidines<br/>Placebos<br/>Prednisone--administration & dosage<br/>Progression-Free Survival<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Rituximab--administration & dosage<br/>Survival Rate<br/>Vincristine--administration & dosage<br/>Young Adult